AbbVie (ABBV) Revenue (2012 - 2026)

AbbVie (ABBV) has reported Revenue for 15 consecutive years, with $17.0 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Revenue rose 10.16% year-over-year to $17.0 billion in Q2 2026; TTM through Jun 2026 was $64.4 billion, a 10.39% increase from a year earlier, with the FY2025 full-year figure at $61.2 billion, up 8.57% from the prior year.
• Revenue was $17.0 billion for Q2 2026 at AbbVie, up from $15.0 billion in the prior quarter.
• Over five years, Revenue peaked at $17.0 billion in Q2 2026 and troughed at $12.2 billion in Q1 2023.
• A 5-year average of $14.5 billion and a median of $14.5 billion in 2022 frame the typical range for Revenue.
• Across the five-year window, Revenue declined 9.7% in 2023 and rose 12.43% in 2026, its largest moves.
• Over 5 years, Revenue stood at $15.1 billion in 2022, then decreased by 5.42% to $14.3 billion in 2023, then advanced by 5.6% to $15.1 billion in 2024, then increased by 10.04% to $16.6 billion in 2025, then climbed by 2.24% to $17.0 billion in 2026.
• The last three Revenue figures came in at $17.0 billion (Q2 2026), $15.0 billion (Q1 2026), and $16.6 billion (Q4 2025), per Business Quant data.